Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This pilot study focuses on the persistence of central nervous system (CNS) immune activation
that has been observed in the presence of 'effective' combination antiretroviral therapy
(cART). Attention to this issue is based on the fear that chronic CNS immunoactivation can
cause indolent brain injury that will eventually compromise brain function as patients
survive for years on treatment. A leading hypothesis explaining this continued
immunoactivation is that viral replication continues within the brain at a level too low for
detection in cerebrospinal fluid (CSF), yet sufficient to stimulate local immunoactivation.
Based on this hypothesis, we propose to use augmented treatment with raltegravir to test
whether additional suppression of this hypothesized CNS HIV-1 replication will reduce
continued CNS immunoactivation.
Phase:
N/A
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Merck Sharp & Dohme Corp. National Institute of Mental Health (NIMH)